Logo image of IDEX.OL

IDEX BIOMETRICS ASA (IDEX.OL) Stock Fundamental Analysis

OSL:IDEX - Euronext Oslo - NO0013107490 - Common Stock - Currency: NOK

0.03  0 (0%)

Fundamental Rating

1

IDEX gets a fundamental rating of 1 out of 10. The analysis compared the fundamentals against 50 industry peers in the Electronic Equipment, Instruments & Components industry. IDEX may be in some trouble as it scores bad on both profitability and health. IDEX does not seem to be growing, but still is valued expensively.


Dividend Valuation Growth Profitability Health

Quickly go to:

0

1. Profitability

1.1 Basic Checks

In the past year IDEX has reported negative net income.
IDEX had a negative operating cash flow in the past year.
IDEX had negative earnings in each of the past 5 years.
IDEX had a negative operating cash flow in each of the past 5 years.
IDEX.OL Yearly Net Income VS EBIT VS OCF VS FCFIDEX.OL Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 -10M -20M -30M

1.2 Ratios

IDEX has a worse Return On Assets (-144.01%) than 92.00% of its industry peers.
IDEX has a worse Return On Equity (-9147.92%) than 90.00% of its industry peers.
Industry RankSector Rank
ROA -144.01%
ROE -9147.92%
ROIC N/A
ROA(3y)-119.85%
ROA(5y)-118.87%
ROE(3y)-228.17%
ROE(5y)-196.92%
ROIC(3y)N/A
ROIC(5y)N/A
IDEX.OL Yearly ROA, ROE, ROICIDEX.OL Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 -100 -200 -300

1.3 Margins

IDEX does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
IDEX.OL Yearly Profit, Operating, Gross MarginsIDEX.OL Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -20K -40K -60K

More info and screens

1

2. Health

2.1 Basic Checks

IDEX does not have a ROIC to compare to the WACC, probably because it is not profitable.
Compared to 1 year ago, IDEX has more shares outstanding
Compared to 5 years ago, IDEX has more shares outstanding
Compared to 1 year ago, IDEX has an improved debt to assets ratio.
IDEX.OL Yearly Shares OutstandingIDEX.OL Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 200M 400M 600M 800M
IDEX.OL Yearly Total Debt VS Total AssetsIDEX.OL Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M 80M

2.2 Solvency

IDEX has an Altman-Z score of -59.74. This is a bad value and indicates that IDEX is not financially healthy and even has some risk of bankruptcy.
The Altman-Z score of IDEX (-59.74) is worse than 90.00% of its industry peers.
IDEX has a Debt/Equity ratio of 12.58. This is a high value indicating a heavy dependency on external financing.
IDEX has a worse Debt to Equity ratio (12.58) than 90.00% of its industry peers.
Industry RankSector Rank
Debt/Equity 12.58
Debt/FCF N/A
Altman-Z -59.74
ROIC/WACCN/A
WACC5.34%
IDEX.OL Yearly LT Debt VS Equity VS FCFIDEX.OL Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 20M -20M 40M 60M 80M

2.3 Liquidity

A Current Ratio of 1.65 indicates that IDEX should not have too much problems paying its short term obligations.
Looking at the Current ratio, with a value of 1.65, IDEX is in line with its industry, outperforming 48.00% of the companies in the same industry.
A Quick Ratio of 0.54 indicates that IDEX may have some problems paying its short term obligations.
IDEX has a worse Quick ratio (0.54) than 86.00% of its industry peers.
Industry RankSector Rank
Current Ratio 1.65
Quick Ratio 0.54
IDEX.OL Yearly Current Assets VS Current LiabilitesIDEX.OL Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M 80M

More info and screens

2

3. Growth

3.1 Past

IDEX shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 70.62%, which is quite impressive.
IDEX shows a very negative growth in Revenue. In the last year, the Revenue has decreased by -82.47%.
Measured over the past years, IDEX shows a quite strong growth in Revenue. The Revenue has been growing by 14.73% on average per year.
EPS 1Y (TTM)70.62%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%74.23%
Revenue 1Y (TTM)-82.47%
Revenue growth 3Y-33.35%
Revenue growth 5Y14.73%
Sales Q2Q%-72.04%

3.2 Future

No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next YN/A
EPS Next 2YN/A
EPS Next 3YN/A
EPS Next 5YN/A
Revenue Next Year49.24%
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
IDEX.OL Yearly Revenue VS EstimatesIDEX.OL Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 200M 400M 600M 800M 1B
IDEX.OL Yearly EPS VS EstimatesIDEX.OL Yearly EPS VS EstimatesYearly EPS VS Estimates 2015 2016 2017 2018 2020 2021 2022 2023 2025 0 0.5 -0.5 -1 -1.5 -2

More info and screens

2

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for IDEX. In the last year negative earnings were reported.
With a Price/Forward Earnings ratio of 0.06, the valuation of IDEX can be described as very cheap.
IDEX's Price/Forward Earnings ratio is rather cheap when compared to the industry. IDEX is cheaper than 100.00% of the companies in the same industry.
The average S&P500 Price/Forward Earnings ratio is at 22.19. IDEX is valued rather cheaply when compared to this.
Industry RankSector Rank
PE N/A
Fwd PE 0.06
IDEX.OL Price Earnings VS Forward Price EarningsIDEX.OL Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 10 20 30

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
IDEX.OL Per share dataIDEX.OL EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 -2 -4 -6

4.3 Compensation for Growth

PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2YN/A
EPS Next 3YN/A

More info and screens

0

5. Dividend

5.1 Amount

IDEX does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

IDEX BIOMETRICS ASA

OSL:IDEX (6/19/2025, 11:05:03 AM)

0.03

0 (0%)

Chartmill FA Rating
GICS SectorInformation Technology
GICS IndustryGroupTechnology Hardware & Equipment
GICS IndustryElectronic Equipment, Instruments & Components
Earnings (Last)05-21 2025-05-21
Earnings (Next)08-15 2025-08-15
Inst Owners1.4%
Inst Owner ChangeN/A
Ins Owners0.62%
Ins Owner ChangeN/A
Market Cap526.41K
Analysts82.86
Price Target13.24 (44033.33%)
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)0%
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)0%
EPS NY rev (3m)0%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)0%
Revenue NY rev (3m)0%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE 0.06
P/S 0.09
P/FCF N/A
P/OCF N/A
P/B 0.37
P/tB N/A
EV/EBITDA N/A
EPS(TTM)-0.28
EYN/A
EPS(NY)0.52
Fwd EY1730.6%
FCF(TTM)-7.58
FCFYN/A
OCF(TTM)-7.58
OCFYN/A
SpS0.32
BVpS0.08
TBVpS-0.23
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -144.01%
ROE -9147.92%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-119.85%
ROA(5y)-118.87%
ROE(3y)-228.17%
ROE(5y)-196.92%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score1
Asset Turnover0.06
Health
Industry RankSector Rank
Debt/Equity 12.58
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr N/A
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 1.65
Quick Ratio 0.54
Altman-Z -59.74
F-Score1
WACC5.34%
ROIC/WACCN/A
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)70.62%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%74.23%
EPS Next YN/A
EPS Next 2YN/A
EPS Next 3YN/A
EPS Next 5YN/A
Revenue 1Y (TTM)-82.47%
Revenue growth 3Y-33.35%
Revenue growth 5Y14.73%
Sales Q2Q%-72.04%
Revenue Next Year49.24%
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y24.99%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year1659.05%
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y58.41%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y58.08%
OCF growth 3YN/A
OCF growth 5YN/A